Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Medtech in China – the impact of reforms

In part one of a two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the impact of reforms on medtech in China.

The Chinese medtech market is one of the largest and fastest-growing in the world, growing at a rate of 12% in 2016 alone. Going forward, one of the key factors that will shape the development of China’s medtech market is the regulatory landscape, including rules governing the industry, government policies relating to the sector and reforms in the space.

There are a few changes expected in the next few years, for example: the government assuming a greater burden of healthcare expenses, the implementation of cost controls through packaged pricing and limiting the markups added by distributors.

There are other regulations and trends affecting China’s healthcare policy, too, as there are ways to handle them.

In June last year, the Office of the Chinese Ministry of Human Resources and Social Security issued The Guidance on the Long-term Nursery Reimbursement Pilot Policy. The policy aimed at providing financial support or care provisions for people with long-term disabilities.

Fifteen pilot cities were selected for the first trial of this policy. It stipulates that the government should raise money by optimising the structure of workers’ medical care accounts; that is, transferring the balance of workers’ medical care funds and regulating the rates for medical reimbursement. This should gradually establish a multi-channel and dynamic financing mechanism.

For long-term care costs and covering related provisions, the reimbursement fund will cover 70% of the total payment.

In the near future, the Chinese government is committed to providing full medical reimbursement coverage for all Chinese citizens. To achieve this goal, the government will improve its management mechanism and involve other social organisations – such as commercial insurance institutions – to handle such services.

The government will simultaneously establish a multi-level, targeted social security system. While some high-end needs may be supplemented by commercial insurance, the government will be responsible for the remaining parts.

At the initial stage of the policy, the medical reimbursement fund will bear most of the financing obligations, without increasing the burden on businesses or individuals. In the long term, individuals and businesses should bear corresponding portions of the payment to ease the financial pressure off the government.

It also makes sense for companies to prepare to compete with the local industry; this involves being able to gauge the chances of profitably surviving the battle in this market segment.

There are 6,000 local Chinese companies, although a majority of these are active in the lower-tech areas. That notwithstanding, they still demonstrate a sizable local manufacturing and sales force that has distinct advantages within the market.

The Chinese (medtech) regulatory system – including the reimbursement process – is required not only to satisfy the standard requirements, which we are acquainted with from most other countries in the world, but is also intended to have other impacts.

As with most regulatory implementations, the central purpose of the Chinese healthcare measures is control. From this central objective, other impacts are achieved and other objectives are brought forward. The key elements include: controlling the financial aspects of healthcare provisions and reimbursements; the adaptations and alterations of the patient care paths that develop in correlation to reimbursement measures; and protection of the local industry.

The preparation efforts required for working with the Chinese administrative system, both in regard to understanding and dealing with it, makes resource deployment shift from the middle or end of the cycle to the beginning or middle of the cycle.

Registration and other pre-launch activities are not abnormal, but the unusually lengthy and complicated trajectory to obtain the proper reimbursement is quite China-specific. While comparable markets, such as Japan, have set up barriers at registration levels, China has an additional minefield at the level of reimbursement, embedded in a difficult tendering and bidding mechanism.

These bidding-related challenges and other factors to consider are:

1) Discrimination. Different employment/status-based categories of people have very different reimbursement conditions; that is, employees, residents, military, the elderly, retirees and so on. all have differing reimbursement entitlements.

2) Regionalism. Reimbursement conditions vary between provinces, cities and even towns.

3) Differences across all factors that determine reimbursement. Different regions and different insurance types have different threshold fees, upper limits and barriers to providing treatments and diagnostics.

4) Concentration of new products in key locations. Key cities and hospitals play an important role in China. It is common for new products and techniques to first be tried out in the key cities and hospitals prior to being considered for nationwide procurement.

Separately, the private sector is expected to play a bigger role in acute care. Despite the fact that this process is proceeding slower than expected – since no specific action plans have been put into place – the number of private hospitals and clinics is increasing rapidly.

Tomorrow we will look at the opportunities in the market.

This piece first appeared on BRINK Asia.

Posted on: 27/07/2017 UTC+08:00


News

Lilly Asia Ventures, which makes venture capital investments in Asia for global pharmaceutical giant Eli Lilly and Company, has closed LAV Biosciences Fund IV, its fourth fund. It took only two months to reach the hard cap of US$450 million.
Summerset Group, New Zealand’s third-largest listed retirement village operator, has posted a 78% jump in profits for the first half of the year of NZ$90.3 million (US$65.9 million).
Q&M Dental Group, which operates the largest network of private dental outlets in Singapore, has reported a decline in profits for the second quarter of the year, though these are the result of the deconsolidation of two subsidiaries.
Hong Kong-listed Common Splendor International Health Industry Group is currently juggling with two acquisitions in China.
IVD and medical imaging company Yestar Healthcare has said that it is in the preliminary stage of possibly acquiring medical device companies in the northern region of China.
Paragon Care, a leading distributor and manufacturer supplying medical equipment to hospitals, has agreed to acquire Medtek for A$649,000 (US$512,759) shares and cash. The company provides biomedical engineering services and preventative maintenance to the medical, scientific, aged care and allied health clients in the Far North Queensland region.
Hospital operation and management group the Hospital Corporation of China (HCC) plans to buy a 70% stake in an unnamed traditional Chinese medicine private hospital in Zhejiang.
For the first half of the year private specialist healthcare provider Singapore Medical Group (SMG) has reported a massive jump in profits on the back of its move into diagnostics and aesthetics.



Analysis

Mercer’s Catherine Li explains how companies in China can avoid common pitfalls when they establish employee health management programmes.
Lieven Jacquemyn, PPP international development director at GE Healthcare Singapore, discusses how governments, providers and investors can work together to bring universal health coverage to the region.
Mercer’s Rose Kwan and Heena Sethi explain how employers can better manage their healthcare benefits.
Susann Roth, senior social development specialist, Asian Development Bank, looks at financing mechanisms to meet the third Sustainable Development Goal.
On the back of an ageing population, strong employment growth and the flow of private investment, medical and health care property will emerge as a major asset class in Western Australian’s commercial property markets according to new analysis by independent West Australian commercial property information and research firm, Y Research.
In the second part of our two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the medtech opportunities in China.
In part one of a two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the impact of reforms on medtech in China.
In what is starting to resemble a comedy of errors, Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China, is having to start work yet again for its A-share offering.


Civica

HealthInvestor Asia Summit

AON

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices